Long-term safety and tolerability of atomoxetine in Japanese adults with attention deficit hyperactivity disorder

Asia-Pacific Psychiatry

Volumn 6, Issue 3, 2014, Pages 292-301

  Hirata, Yuko ^a   Goto, Taro ^a   Takita, Yasushi ^a   Trzepacz, Paula T ^a   Allen, Albert J ^a   Ichikawa, Hironobu ^b   Takahashi, Michihiro ^a,c  

^a ELI LILLY AND COMPANY   (United States)

^b TOKYO METROPOLITAN CHILDREN'S MEDICAL CENTER   (Japan)

^c Terauchi Takahashi Psychiatric Clinic   (Japan)

Author keywords

Adult; Asian; Atomoxetine; Attention deficit hyperactivity disorder; Safety

Indexed keywords

ATOMOXETINE; CYTOCHROME P450 2D6; PLACEBO; ADRENERGIC RECEPTOR AFFECTING AGENT; PROPYLAMINE;

ABDOMINAL DISCOMFORT; ADULT; ADULT DISEASE; ANAPHYLAXIS; ARTICLE; ATTENTION DEFICIT DISORDER; BACKACHE; BODY WEIGHT; BODY WEIGHT DISORDER; CONSTIPATION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DECREASED APPETITE; DIASTOLIC BLOOD PRESSURE; DIVERTICULITIS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV-TR; DYSURIA; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; HEADACHE; HEART PALPITATION; HUMAN; JAPANESE (PEOPLE); LONG TERM CARE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NAUSEA; OPEN STUDY; PERITONITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; THIRST; TRAUMATIC AMPUTATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UTERUS MYOMA; VOMITING; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; JAPAN; TIME;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; FEMALE; HUMANS; JAPAN; MALE; PROPYLAMINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929938812     PISSN: 17585864     EISSN: 17585872     Source Type: Journal    
DOI: 10.1111/appy.12119     Document Type: Article

References (32)

1. Adler L., Cohen J. (2004) Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 27, 187-201.
2. Adler L.A., Spencer T.J., Williams D.W., Moore R.J., Michelson D. (2008) Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord. 12, 248-253.
3. Adler L.A., Spencer T., Brown T.E., etal. (2009) Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol. 29, 44-50.
4. Agarwal R., Goldenberg M., Perry R., IsHak W.W. (2012) The quality of life of adults with attention deficit hyperactivity disorder: a systematic review. Innov Clin Neurosci. 9, 10-21.
5. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. text rev. American Psychiatric Association, Washington, DC.
6. Arnsten A.F., Pliszka S.R. (2011) Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacol Biochem Behav. 99, 211-216.
7. Barkley R.A. (1998) Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment, 2nd edn. Guilford Press, New York.
8. Barkley R.A., Fischer M. (2011) Predicting impairment in major life activities and occupational functioning in hyperactive children as adults: self-reported executive function (EF) deficits versus EF tests. Dev Neuropsychol. 36, 137-161.
9. Biederman J., Mick E., Faraone S.V. (2000) Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry. 157, 816-818.
10. Biederman J., Petty C., Fried R., etal. (2006) Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 163, 1730-1738.
11. Brod M., Perwien A., Adler L., Spencer T., Johnston J. (2005) Conceptualization and assessment of quality of life for adults with attention-deficit/hyperactivity disorder. Prim Psychiatry. 12, 58-64.
12. Brod M., Johnston J., Able S., Swindle R. (2006) Validation of the adult attention-deficit/hyperactivity disorder quality-of-life Scale (AAQoL): a disease-specific quality-of-life measure. Qual Life Res. 15, 117-129.
13. Brown T.E., Holdnack J., Saylor K., etal. (2011) Effect of atomoxetine on executive function impairments in adults with ADHD. J Atten Disord. 15, 130-138.
14. Buitelaar J.K., Michelson D., Danckaerts M., etal. (2007) A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry. 61, 694-699.
15. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (2011) Canadian ADHD Practice Guidelines, 3rd edn. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance, Toronto, Canada.
16. Conners C.K., Erhardt D., Sparrow E. (1999) Conners' Adult ADHD Rating Scales (CAARS). Multi-Health Systems, North Tonawanda, New York.
17. Day R.O., Williams K.M. (2007) Open-label extension studies: do they provide meaningful information on the safety of new drugs? Drug Saf. 30, 93-105.
18. Faraone S.V., Biederman J., Spencer T., etal. (2000) Attention-deficit/hyperactivity disorder in adults: an overview. Biol Psychiatry. 48, 9-20.
19. Hirata Y., Goto T., Takita Y., etal. (2012) Efficacy and safety of atomoxetine in Asian adults with ADHD: a multinational 10-week randomized, double-blind placebo-controlled Asian study. Results presented (poster) at the International College of Neuropsychopharmacology (CINP) World Congress, Stockholm, Sweden. (Article submitted for publication).
20. Matsui A., Azuma J., Witcher J.W., etal. (2012) Pharmacokinetics, safety, and tolerability of atomoxetine and effect of CYP2D6*10/*10 genotype in healthy Japanese men. J Clin Pharmacol. 52, 388-403.
21. Matza L.S., Johnston J.A., Faries D.E., Malley K.G., Brod M. (2007) Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL). Qual Life Res. 16, 1511-1520.
22. Michelson D., Adler L., Spencer T., etal. (2003) Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 53, 112-120.
23. National Collaborating Centre for Mental Health (UK) (2009) Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults. British Psychological Society, Leicester, UK.
24. Nigg J.T., Stavro G., Ettenhofer M., Hambrick D.Z., Miller T., Henderson J.M. (2005) Executive functions and ADHD in adults: evidence for selective effects on ADHD symptom domains. J Abnorm Psychol. 114, 706-717.
25. Roth R.M., Isquith P.K., Gioia G.A. (2005) BRIEF-A: Behavior Rating Inventory of Executive Function - Adult Version: Professional Manual. Psychological Assessment Resources, Lutz, FL.
26. Santosh P.J., Sattar S., Canagaratnam M. (2011) Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults. CNS Drugs. 25, 737-763.
27. Spencer T., Biederman J., Wilens T.E., Faraone S.V. (1998) Adults with attention-deficit/hyperactivity disorder: a controversial diagnosis. J Clin Psychiatry. 59(Suppl 7), 59-68.
28. Takahashi M., Takita Y., Goto T., etal. (2011) An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder. Psychiatry Clin Neurosci. 65, 55-63.
29. Takahashi M., Goto T., Takita Y., Chung S., Wang Y., Shur-Fen Gau S. (2012) Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder. Asia Pac Psychiatry. doi: 10.1111/j.1758-5872.2012.00204.x.
30. Weiss G., Hechtman L.T. (1993) Hyperactive Children Grown Up: ADHD in Children, Adolescents, and Adults. Guilford Press, New York.
31. Wilens T.E., Morrison N.R., Prince J. (2011) An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults. Expert Rev Neurother. 11, 1443-1465.
32. Young J.L., Sarkis E., Qiao M., Wietecha L. (2011) Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol. 34, 51-60.